Thimble Point Acquisition Corp

Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The firm aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. It has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. The company’s lead product, reSET, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Its second product, reSET-O, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear's third product, Somryst for the treatment of chronic insomnia, was the first PDT submitted through the FDA's traditional 510(k) pathway while simultaneously reviewed through the FDA's Software Precertification Pilot Program. The company was founded on December 1, 2020 and is headquartered in Boston, MA.

The full company name is Sanswire Technologies Inc.

Sleep Health Leader Further Elevates Behavioral Sleep Care Management Program Sleep Health Leader Further Elevates Behavioral Sleep Care Management Program

Nox Health Closes Acquisition of Somryst, the Only FDA-Cleared Digital Insomnia Treatment, From Pear Therapeutics

Pear Therapeutics (NASDAQ: PEAR ) stock is falling on Friday after the company's recent bankruptcy filing continues to weigh on its shares. Pear Therapeutics announced its bankruptcy filing while markets were closed for Black Friday.

Why Is Pear Therapeutics (PEAR) Stock Down 26% Today?

BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc. (Nasdaq: PEAR) (“the Company”), a company focused on developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that the Company and its wholly owned subsidiary, Pear Therapeutics (US), Inc. (collectively, the “Debtors”) each voluntarily filed for protection under chapter 11 (“Chapter 11”) of the U.S. Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) and they intend to pursue a sale of the business or assets under section 363 of the Bankruptcy Code.

Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process

Pear Therapeutics (NASDAQ: PEAR ) stock is climbing higher on Tuesday despite the company's plans to explore strategic alternatives. That news was first announced by the company before markets opened on Friday.

Why Is Pear Therapeutics (PEAR) Stock Up 21% Today?

BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc. (Nasdaq: PEAR) (“the Company”), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it is engaged in a process to explore strategic alternatives to maximize shareholder value. The Company has engaged MTS Health Partners, L.P. to act as the Company's exclusive financial advisor to assist in evaluating potential alternatives. MTS Health Partners is a leading boutique investment bank that provides strategic and financial advice to the healthcare industry.

Pear Therapeutics Announces Process Exploring Strategic Alternatives

BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate in the 43rd Annual Cowen Healthcare Conference being held March 6-8, 2023 in Boston. Corey McCann, M.D., Ph.D., President and CEO, will represent the Company in an analyst-led fireside chat on Monday, March 6 at 9:10 a.m. Eastern Time.

Pear Therapeutics to Participate in 43rd Annual Cowen Healthcare Conference

BOSTON--( BUSINESS WIRE )--Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 14 - 16, 2023 in Snowbird, UT. Pear management will participate virtually in 1x1 meetings at the conference.

Pear Therapeutics to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

BOSTON--( BUSINESS WIRE )--Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today the expansion of its collaboration with BrightView Health, an addiction treatment provider that offers evidence-based, outpatient addiction treatment programs. This initiative is designed to provide eligible adults suffering from substance use disorder (SUD) and opioid use disorder (OUD) access to reSET® and reSET-O®. BrightView, an innovative and patient-focused leader in SUD and OUD treatment, began piloting Pear's products in its centers across six locations in Kentucky and Ohio in early 2022, and intends to expand the initiative across Kentucky, Ohio, Delaware, Massachusetts, and Virginia. BrightView currently has over 80 locations across 8 states.

Pear Therapeutics and BrightView Health Expand Pilot Program to Provide Prescription Digital Therapeutics for the Treatment of Substance Use Disorders

The heavy selling pressure might have exhausted for Pear Therapeutics, Inc. (PEAR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Pear Therapeutics, Inc. (PEAR) Loses -17.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

BOSTON--( BUSINESS WIRE )-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the inclusion of its PDTs reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List (PDL). reSET and reSET-O, the only FDA-authorized PDTs for the treatment of substance use disorder and opioid use disorder, respectively, have been added to the Florida Medicaid PDL, effective January 1, 2023.

Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List

BOSTON--( BUSINESS WIRE )--Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in Citi's BioTech C-Suite Virtual Fireside Chat Series on Tuesday, January 24 at 11:00 a.m. ET. Corey McCann, M.D., Ph.D., President and CEO, will participate in the Citi analyst-hosted fireside chat to discuss Pear's progress on market access.

Pear Therapeutics to Participate in Citi's BioTech C-Suite Virtual Fireside Chat Series

BOSTON--( BUSINESS WIRE )--The California Department of Health Care Services (DHCS) has selected Pear Therapeutics, Inc. (Nasdaq: PEAR), a leader in developing and commercializing software-based medicines, to support the implementation of the Recovery Incentives: California's Contingency Management Program. Contingency management is an evidence-based, cost-effective treatment that provides motivational incentives to treat individuals living with stimulant use disorder and support their path to recovery.

California Department of Health Care Services Awards Contract to Pear Therapeutics to Support the Recovery Incentives Program

BOSTON & DEVON, Pa.--( BUSINESS WIRE )--Pear Therapeutics, Inc. (Nasdaq: PEAR) (“Pear”), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced an agreement with COEUS HealthCare, LLC (“COEUS”), a leading life sciences technology and consulting firm, to utilize its outcomes and evidence-based reimbursement adjudication platform, COEBRA™ to help enable value-based contracting. As Pear continues to engage in clinical and contractual conversations with state Medicaid programs, its agreement with COEUS makes it easier for individual states to engage in value-based contracting to access Pear's PDTs. Pear's commercial products, reSET® and reSET-O®, are among a limited number of products initially included in the solution and are the only PDTs on the platform.

Pear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital Therapeutics

BOSTON & BRENTWOOD, Tenn.--( BUSINESS WIRE )--Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the expansion of its collaboration with Spero Health, an integrated healthcare services organization specializing in local and affordable outpatient care for individuals suffering from substance use disorders, to provide adults suffering from substance use disorder (SUD) and opioid use disorder (OUD) access to reSET® and reSET-O®, for each respective condition. Spero Health, which has implemented reSET and reSET-O at 14 locations in Kentucky, intends to expand access to eligible patients at its 99 locations throughout Indiana, Kentucky, Ohio, Tennessee, West Virginia, and Virginia. The expansion is part of Spero Health's commitment to increase patient engagement and retention in recovery by offering FDA-authorized innovative treatment options.

Pear Therapeutics and Spero Health to Expand Access to Prescription Digital Therapeutics for People in Recovery Across Multiple Locations and States

BOSTON--( BUSINESS WIRE )--Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced data from a real-world analysis of engagement, substance use, and retention patterns in patients diagnosed with substance use disorder who use alcohol and were treated with reSET. The real-world data were presented during the 33rd meeting of the American Association of Addiction Psychiatry held from December 8-11, 2022, in Naples, FL.

Pear Therapeutics Presents Real-World Clinical Data Assessing Engagement and Abstinence in Patients with Alcohol Use Disorders Using reSET® at AAAP

BOSTON--( BUSINESS WIRE )--Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022. Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at 12:10 p.m. ET.

Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference

Pear is focusing on its established substance abuse products now, putting development on a hold. Performance has been good into onboarding payors that have good coverage in markets where substance abuse is a problem.

Pear Has Captive Markets With reSET, Guides $30 Million In 2023

Pear Therapeutics Inc. (NASDAQ:PEAR ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Meara Murphy – Senior Director-Corporate Communications Corey McCann – President and Chief Executive Officer Ronan O'Brien – General Counsel Julia Strandberg – Chief Commercial Officer Yuri Maricich – Chief Medical Officer Chris Guiffre – Chief Financial Officer and Chief Operating Officer Erin Brenner – Chief Product Development Officer Conference Call Participants Eric Percher – Nephron Research Marie Thibault – BTIG Neena Bitritto-Garg – Citi Steve Braun – Cowen Keay Nakae – Chardan Rahul Rakhit – LifeSci Capital Operator Good afternoon, everyone. Welcome to the Pear Therapeutics Third Quarter 2022 Earnings Conference Call.

Pear Therapeutics Inc. (PEAR) Q3 2022 Earnings Call Transcript

BOSTON--( BUSINESS WIRE )--Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its third quarter ended September 30, 2022.

Pear Therapeutics Reports Third Quarter 2022 Results

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Participate in the BTIG Digital Health Forum

Pear Therapeutics to Participate in the BTIG Digital Health Forum

BOSTON--(BUSINESS WIRE)--Pear Presents Real-World Data Showing Reduction in Healthcare Resource Utilization and Associated Costs in Adults Using Somryst® at ISPOR Europe

Pear Therapeutics Presents Real-World Data Showing Reduction in Healthcare Resource Utilization and Associated Costs in Adults Using Somryst® at ISPOR Europe

State of Wisconsin to Provide Access to Prescription Digital Therapeutics to Help Local Communities Fight Against Addiction Crisis

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference

Pear Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Issue Third Quarter 2022 Financial Results on Monday, November 14, 2022

Pear Therapeutics to Issue Third Quarter 2022 Financial Results on Monday, November 14, 2022

BOSTON--(BUSINESS WIRE)--Pear Therapeutics Announces Publication of Real-World Data Showing High Rates of Engagement, Retention and Abstinence with reSET®

News for Thimble Point Acquisition Corp Stock (PEAR)